Neuroimmunology Research Unit, Health Research Institute, Hospital Universitario Y Politécnico La Fe, Avda. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
Neurology Department, Hospital Universitario Y Politécnico La Fe, Avda. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
Sci Rep. 2022 Oct 29;12(1):18238. doi: 10.1038/s41598-022-23088-x.
The information provided by a person with multiple sclerosis (MS) may anticipate changes in the course of the disease. To explore the role of a set of standardized patient-reported outcomes (PRO) in predicting disability progression in MS an observational study was conducted in two cohorts of 30 and 86 persons with progressive MS (pwPMS) and relapsing MS (pwRMS), respectively. The associations between baseline clinical, biochemical variables and results on MS quality of life scale (MusiQol), Modified Fatigue Impact Scale (MFIS) and Beck Depression Inventory II (BDI-II) were analyzed. The progression of disability after 2 years of follow-up in pwRMS was investigated. We show that PRO differentiated pwRMS and pwPMS cohorts with lower MusiQoL and higher MFIS and BDI-II scores in the latter. Only MFIS was correlated with disability in pwRMS and high scores in the physical MFIS domain associated with worse performance in 9HPT, and a trend in T25FW and SDMT. Instead, the cognitive MFIS domain was correlated with CHI3L1 in cerebrospinal fluid, a biomarker of progression. At the end of the study, global MFIS and BDI-II were found to be independent risk factors for disability independent of relapse. Although all PRO measures explored were altered in pwPMS, baseline MFIS discriminated current and prospective disability in pwRMS, identifying patients at risk of progression.
多发性硬化症(MS)患者提供的信息可能预示着疾病进程的变化。为了探索一组标准化的患者报告结局(PRO)在预测 MS 残疾进展中的作用,在两个队列中进行了一项观察性研究,分别纳入了 30 名进展型多发性硬化症(pwPMS)和 86 名复发型多发性硬化症(pwRMS)患者。分析了基线临床、生化变量与 MS 生活质量量表(MusiQol)、改良疲劳影响量表(MFIS)和贝克抑郁量表 II(BDI-II)结果之间的关系。研究了 pwRMS 患者在 2 年随访后的残疾进展情况。我们发现,PRO 可以区分 pwRMS 和 pwPMS 队列,后者的 MusiQoL 评分较低,MFIS 和 BDI-II 评分较高。只有 MFIS 与 pwRMS 中的残疾相关,MFIS 物理域的高分与 9HPT 表现更差相关,T25FW 和 SDMT 呈趋势相关。而认知 MFIS 域与脑脊液中的 CHI3L1 相关,CHI3L1 是进展的生物标志物。在研究结束时,发现全球 MFIS 和 BDI-II 是独立于复发的残疾的独立危险因素。尽管在 pwPMS 中探索的所有 PRO 措施都发生了改变,但基线 MFIS 可以区分 pwRMS 中的当前和未来残疾,从而识别出有进展风险的患者。